시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 불안장애 및 우울증 치료 시장 보고서(2025년)
Anxiety Disorders And Depression Treatment Global Market Report 2025
상품코드 : 1760462
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,222,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 8,993,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,765,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

불안장애 및 우울증 치료 시장 규모는 향후 수 년간 강력한 성장이 전망됩니다. 예측 기간 동안의 성장은 정신 건강 관리를 지원하는 정부 이니셔티브, 현대 사회의 스트레스 수준 증가, 정신 건강 치료를 위한 광범위한 보험 보장, 업무 관련 스트레스 및 소진 증가, 원격 의료 및 온라인 치료 서비스의 확대에 기인할 수 있습니다. 예측 기간의 주요 추세는 약리학적 치료의 발전, 진단 툴이나 진단 기술의 개선, 디지털 정신 건강 플랫폼이나 앱의 출현, 심리 치료 기술의 진보, 부작용이 적은 혁신적인 항우울제의 개발 등을 들 수 있습니다.

정신 건강 장애의 유병률 증가는 앞으로 수 년간 불안장애 및 우울증 치료 시장의 확대를 촉진할 것으로 예측됩니다. 경제적 불안정과 소셜 미디어와의 상시 접속 등, 사회적 스트레스의 증대는 불안이나 우울의 감정을 증폭시켜, 정신 루스 장애 증가에 기여하고 있습니다. 불안과 우울증에 대처하는 것은 정신 건강 장애를 관리하는 데 필수적입니다. 영국 국민건강서비스(NHS)가 발표한 보고서에 따르면, 2023년 8세에서 16세 아동의 20.3%가 정신 질환을 앓고 있는 것으로 의심되었습니다. 또한, 20세에서 25세 사이의 사람들 중 21.7%와 17세에서 19세 사이의 사람들 중 23.3%가 영향을 받았습니다. 이와 같이, 정신 질환의 유병률이 상승하고 있는 것이, 불안장애 및 우울증 치료 시장의 성장을 가속하고 있습니다.

불안장애 및 우울증 치료 시장의 주요 기업은 약물을 사용하지 않는 치료법을 제공하기 때문에 경두개 자기 자극(TMS) 요법과 같은 고급 솔루션의 개발에 점점 더 집중하고 있습니다. 예를 들어, 2024년 3월 미국 의료기기 제조업체인 뉴로네틱스사는 미국 식품의약국(FDA)이 뉴로스터 애드 반스드 테라피를 15-21세 청년의 주요 우울증 장애(MDD)의 보조 치료로 허가했다고 발표했습니다. 이는 이 연령대에 대한 최초이자 유일한 FDA 승인 TMS 치료법이며, NeuroStar에 대한 네 번째 승인 사용입니다. 이 플랫폼은 청소년에 대한 치료의 안전성과 효능에 관한 중요한 데이터를 보여주었으며, 분석 대상이 된 1,169명의 청소년 중 78%에서 우울증의 중증도가 크게 감소한 것으로 나타났습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

SHW
영문 목차

영문목차

Anxiety disorders and depression treatment refers to the various medical, psychological, and lifestyle interventions used to manage and alleviate the symptoms of anxiety and depressive disorders. The goal of these treatments is to improve patients' mental well-being, daily functioning, and overall quality of life.

The primary treatment approaches for anxiety disorders and depression include pharmacological treatment, psychotherapy, and a combination of both. Pharmacological treatment involves the use of medications to manage symptoms of anxiety and depression. It is utilized for various conditions such as obsessive-compulsive disorder, major depressive disorder, phobias, and others, affecting adults, adolescents, and children, and is distributed through hospital pharmacies, retail pharmacies, and other channels.

The anxiety disorders and depression treatment market research report is one of a series of new reports from The Business Research Company that provides anxiety disorders and depression treatment market statistics, including anxiety disorders and depression treatment industry global market size, regional shares, competitors with a anxiety disorders and depression treatment market share, detailed anxiety disorders and depression treatment market segments, market trends and opportunities, and any further data you may need to thrive in the anxiety disorders and depression treatment industry. This anxiety disorders and depression treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anxiety disorders and depression treatment market size has grown strongly in recent years. It will grow from $14.06 billion in 2024 to $14.83 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth during the historic period can be attributed to factors such as the rising prevalence of anxiety disorders and depression, increased awareness of mental health issues, greater acceptance of mental health treatment, the expanding pipeline of new psychiatric drugs, and growing investment in mental health research.

The anxiety disorders and depression treatment market size is expected to see strong growth in the next few years. It will grow to $18.17 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. The growth during the forecast period can be attributed to government initiatives supporting mental health care, increasing stress levels in modern society, broader insurance coverage for mental health treatments, a rise in work-related stress and burnout, and the expansion of telemedicine and online therapy services. Key trends in the forecast period include advancements in pharmacological treatments, improvements in diagnostic tools and techniques, the emergence of digital mental health platforms and apps, progress in psychotherapy techniques, and the development of innovative antidepressants with fewer side effects.

The growing prevalence of mental health disorders is expected to drive the expansion of the anxiety disorders and depression treatment market in the coming years. Mental health disorders affect a person's thinking, emotions, behavior, or mood, often disrupting daily life. Increasing societal stress, including economic instability and constant social media connectivity, contributes to the rise in mental health disorders by amplifying feelings of anxiety and depression. Addressing anxiety and depression is essential for managing mental health disorders, as effectively treating these underlying conditions can significantly reduce the impact of related issues, leading to improved overall well-being and daily functioning. For example, a report published by the National Health Service in November 2023 revealed that 20.3% of children aged eight to sixteen were suspected to have a mental illness in 2023. Additionally, 21.7% of individuals aged 20 to 25 and 23.3% of those aged 17 to 19 were affected. Thus, the rising prevalence of mental health disorders is set to propel the growth of the anxiety disorders and depression treatment market.

Leading companies in the anxiety disorders and depression treatment market are increasingly focusing on developing advanced solutions, such as transcranial magnetic stimulation (TMS) therapy, to provide drug-free treatment options. TMS therapy is a non-invasive procedure that uses magnetic pulses to target specific areas of the brain, helping to alleviate symptoms of depression and other mental health conditions. For example, in March 2024, Neuronetics Inc., a US-based medical device company, announced that the US Food and Drug Administration (FDA) had granted clearance for NeuroStar Advanced Therapy as an adjunct treatment for major depressive disorder (MDD) in adolescents aged 15-21. This marks the first and only FDA-approved TMS therapy for this age group, and it represents the fourth approved use for NeuroStar. The platform demonstrated key data on the safety and efficacy of the treatment for adolescents, with 78% of the 1,169 adolescents analyzed showing a significant reduction in the severity of their depression symptoms.

In April 2025, Johnson & Johnson, a US-based pharmaceutical company, acquired Intra-Cellular Therapies for an undisclosed amount. This acquisition bolsters Johnson & Johnson's neuroscience division by adding CAPLYTA (lumateperone), a treatment for schizophrenia and bipolar depression, to its portfolio, along with a promising pipeline for other neuropsychiatric and neurodegenerative disorders. Intra-Cellular Therapies is a US-based company specializing in depression medications.

Major players in the anxiety disorders and depression treatment market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., H. Lundbeck A/S, Neurocrine Biosciences Inc., Alkermes plc, Relmada Therapeutics Inc., Headspace Health, COMPASS Pathways plc, Talkspace Inc., Ginger, Axsome Therapeutics Inc., Mind Medicine Inc., Woebot Health Inc., Sage Therapeutics Inc., Happify Health, and Atai Life Sciences N.V.

North America was the largest region in the anxiety disorders and depression treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anxiety disorders and depression treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anxiety disorders and depression treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anxiety disorders and depression treatment market consists of revenues earned by entities by providing services such as medication management, online counseling, crisis intervention services, and behavioral health coaching. The market value includes the value of related goods sold by the service provider or included within the service offering. The anxiety disorders and depression treatment market also includes sales of mood stabilizers, psychotherapy apps, nutritional supplements, and mental health wearables. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anxiety Disorders And Depression Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anxiety disorders and depression treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for anxiety disorders and depression treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anxiety disorders and depression treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Anxiety Disorders And Depression Treatment Market Characteristics

3. Anxiety Disorders And Depression Treatment Market Trends And Strategies

4. Anxiety Disorders And Depression Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Anxiety Disorders And Depression Treatment Growth Analysis And Strategic Analysis Framework

6. Anxiety Disorders And Depression Treatment Market Segmentation

7. Anxiety Disorders And Depression Treatment Market Regional And Country Analysis

8. Asia-Pacific Anxiety Disorders And Depression Treatment Market

9. China Anxiety Disorders And Depression Treatment Market

10. India Anxiety Disorders And Depression Treatment Market

11. Japan Anxiety Disorders And Depression Treatment Market

12. Australia Anxiety Disorders And Depression Treatment Market

13. Indonesia Anxiety Disorders And Depression Treatment Market

14. South Korea Anxiety Disorders And Depression Treatment Market

15. Western Europe Anxiety Disorders And Depression Treatment Market

16. UK Anxiety Disorders And Depression Treatment Market

17. Germany Anxiety Disorders And Depression Treatment Market

18. France Anxiety Disorders And Depression Treatment Market

19. Italy Anxiety Disorders And Depression Treatment Market

20. Spain Anxiety Disorders And Depression Treatment Market

21. Eastern Europe Anxiety Disorders And Depression Treatment Market

22. Russia Anxiety Disorders And Depression Treatment Market

23. North America Anxiety Disorders And Depression Treatment Market

24. USA Anxiety Disorders And Depression Treatment Market

25. Canada Anxiety Disorders And Depression Treatment Market

26. South America Anxiety Disorders And Depression Treatment Market

27. Brazil Anxiety Disorders And Depression Treatment Market

28. Middle East Anxiety Disorders And Depression Treatment Market

29. Africa Anxiety Disorders And Depression Treatment Market

30. Anxiety Disorders And Depression Treatment Market Competitive Landscape And Company Profiles

31. Anxiety Disorders And Depression Treatment Market Other Major And Innovative Companies

32. Global Anxiety Disorders And Depression Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anxiety Disorders And Depression Treatment Market

34. Recent Developments In The Anxiety Disorders And Depression Treatment Market

35. Anxiety Disorders And Depression Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기